Login to Your Account



Of 27 NMES, ONLY 2 WERE BIOLOGICS

Biologic new molecular entities approvals are nothing to write home about

By Mari Serebrov
Washington Editor

Friday, January 17, 2014
To say 2013 was not a banner year for novel biologic approvals would be an understatement. The FDA approved 27 new molecular entities (NMEs) last year, but only two were biologics – Gazyva (obinutuzumab) and Kadcyla (ado-trastuzumab emtansine). Both were developed by the same company, Roche AG subsidiary Genentech Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription